FundedIQ
Biotechnology

Crossbow Therapeutics

Crossbow Therapeutics develops immunotherapies that focus on engineering immune cells to target disease-specific antigens. The company builds platforms that combine antibody discovery with cell therapy approaches to direct immune responses toward cancer cells. Its work involves designing molecules that guide immune cells to recognize and eliminate targets with greater specificity. Crossbow Therapeutics conducts research and development activities that integrate protein engineering, immunology, and translational science. The company also advances preclinical programs to evaluate safety and effectiveness of its therapeutic candidates.

www.crossbowtx.com 11-50 employees
Total raised
$77.0M
Rounds
1
Latest
Series B
Mar 2026

Crossbow Therapeutics develops immunotherapies that focus on engineering immune cells to target disease-specific antigens. The company builds platforms that combine antibody discovery with cell therapy approaches to direct immune responses toward cancer cells. Its work involves designing molecules that guide immune cells to recognize and eliminate targets with greater specificity. Crossbow Therapeutics conducts research and development activities that integrate protein engineering, immunology, and translational science. The company also advances preclinical programs to evaluate safety and effectiveness of its therapeutic candidates.

Crossbow Therapeutics has raised $77.0M across 1 round. Its most recent round was a Series B of $77.0M in Mar 2026. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Mar 18, 2026
Series B
$77.0M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Crossbow Therapeutics is featured in

Similar companies

Semarion

Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.

Series Unknown $3.8M
VolitionRx

Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based malignant growth tests to analyze a scope of diseases precisely. The tests depend on the study of Nucleosomics, which is the act of distinguishing and estimating nucleosomes in the circulation system or other natural liquid which means that illness is available. As disease screening programs become an ever increasing number of far and wide, its items mean to assist with diagnosing a scope of tumors rapidly, basically, precisely, and cost-really. Early analysis can possibly draw out the existence of patients as well as to work on their personal satisfaction. Volition's innovative work exercises are right now focused in Belgium, with extra workplaces in London, Texas, and Singapore, as the organization centers around putting up its demonstrative items for sale to the public first in Europe, then, at that point, in the U.S. furthermore, around the world.

Series Unknown $2.3M
PhenoTips

PhenoTips is a computer software company that provides solution for clinical genetics, phenotyping, and human phenotype ontology. It offers smart software solutions streamlined for clinical use that can be integrated with existing electronic health records. The company was founded in 2014 and headquartered in Ontario, Canada.

Series Unknown
Ammortal

Ammortal is a healthcare services company that offers bio-optimization services.

Series Unknown $25.0M
Omniox

Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.

Series Unknown $24.1M
Swaza

Swaza develops nanotechnology-based therapeutics designed to address critical medical conditions involving impaired oxygen delivery and tissue healing. The company focuses on a nanofluid breathing aid, AeroHeal, which delivers oxygen and removes carbon dioxide in patients with compromised lungs, eliminating the need for invasive ventilation. Their primary product, SWAZA-1, is a non-invasive nanofluid that facilitates gas exchange in damaged lungs. Additionally, SWAZA-2 is an oxygen-enriched biomaterial aimed at enhancing wound healing, and SWAZA-3 is a thermoreversible enema intended for emergency oxygenation.

Seed $400k
Immusoft

A cell therapy business called Immusoft is dedicated to creating revolutionary treatments for uncommon diseases by leveraging sustained delivery of therapeutic proteins from a patient's own cells. Immune System Programming (ISPTM), a technology platform being developed by the company, alters a patient's B cells and teaches them to create gene-encoded medications. The ISP-reprogrammed B cells develop into tiny drug factories that are anticipated to live in patients for many years and give therapeutic effect. The business is based in Seattle, Washington.

Series Unknown $15.0M
Charlotte's Web
Series Unknown $74.4M
Centivax

Defeat the mutants.

Series Unknown $37.0M
Pegasus Biotech

At Pegasus Biotech, our goal is to collaborate with clients to introduce innovative advancements to the global human and animal health sectors. We specialize in guaranteeing that the development processes for client projects, whether in the early stages or transitioning to production, lead to successful products that meet global regulatory standards.

Series Unknown $360k
Artelo Biosciences

Artelo Biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. Its programmes have the potential to dramatically improve patient care in major markets.

Series Unknown $11.0M
Avacta Group

Avacta Group plc is a provider of technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. It is engaged in the research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. The Company has two segments: Analytical and Animal Health. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Company’s subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited, TheraGenetics Limited and TheraGenetics Inc. ###Readybuy Plc acquires Avacta Ltd in a reverse merger and changed name to Avacta Group Plc in 2004. Readybuy was founded in 2003.###

Series Unknown $13.3M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.